Story perspectives

Sun Pharma Buys Organon for $11.75 B, Hits $12.4 B Revenue

4/27/2026

Summary

Story summary

Sun Pharmaceutical Industries announced an all-cash acquisition of Organon & Co. for $11.75 billion at $14 per share.
Both boards approved the deal, slated to close in early 2027 pending approvals.
The transaction will lift Sun Pharma’s revenue to $12.4 billion, moving it into the global top 25 and into the top three for women’s health and the seventh-largest biosimilar producer.
Sun Pharma will fund the purchase with cash reserves and committed bank financing.

History

Historical Context

In July 2002 Pfizer announced a $60 billion deal to buy Pharmacia, completed in April 2003, adding celecoxib and expanding its pipeline after the 2000 Warner-Lambert purchase that made it the world’s second-largest drugmaker. The merger sparked antitrust reviews by the FTC and set a precedent for later cross-border pharma consolidations such as Sun’s 2024 Organon bid.

1 of 2

Story summary

Sun Pharmaceutical Industries announced an all-cash acquisition of Organon & Co. for $11.75 billion at $14 per share.
Both boards approved the deal, slated to close in early 2027 pending approvals.
The transaction will lift Sun Pharma’s revenue to $12.4 billion, moving it into the global top 25 and into the top three for women’s health and the seventh-largest biosimilar producer.
Sun Pharma will fund the purchase with cash reserves and committed bank financing.

1 / 2